Lorlatinib
NA
.svg)
Drug Status
Government Approvals
US(FDA), UK(BNF)
WHO Essential Medicine
NO
Known Teratogen
No
Pharmaceutical Class
Kinase Inhibitor
Controlled Drug Substance
No
Lorlatinib
Summary
Lorlatinib is used to treat a type of lung cancer known as ALK-positive non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
Lorlatinib works by targeting and inhibiting the activity of the ALK protein, which is involved in the growth and spread of cancer cells. By blocking this protein, Lorlatinib helps to slow down or stop the proliferation of cancer cells.
The usual daily dose of Lorlatinib for adults is 100 mg. It is taken orally, once daily, with or without food. It's important not to chew, crush, or split the tablets.
Common side effects of Lorlatinib include edema, peripheral neuropathy, weight gain, cognitive effects, fatigue, shortness of breath, joint pain, diarrhea, mood effects, and cough. Serious side effects can include liver damage, central nervous system effects, high cholesterol, heart block, lung disease, high blood pressure, and high blood sugar.
Lorlatinib can cause serious liver damage when used with strong CYP3A inducers. It can also cause central nervous system effects, high cholesterol, heart block, lung disease, high blood pressure, and high blood sugar. It is contraindicated in patients taking strong CYP3A inducers.
Indications and Purpose
How does Lorlatinib work?
Lorlatinib is a kinase inhibitor that targets and blocks the action of the abnormal ALK protein, which is responsible for the growth and spread of cancer cells in ALK-positive non-small cell lung cancer. By inhibiting this protein, Lorlatinib helps to slow or stop the progression of the disease.
Is Lorlatinib effective?
Lorlatinib has been shown to be effective in treating ALK-positive non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Clinical trials have demonstrated significant improvements in progression-free survival and overall response rates in patients treated with Lorlatinib compared to other treatments.
What is Lorlatinib?
Lorlatinib is used to treat ALK-positive non-small cell lung cancer (NSCLC) that has spread to other parts of the body. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, helping to stop or slow the spread of cancer cells. Lorlatinib is taken orally, usually once daily.
Directions for Use
For how long do I take Lorlatinib?
Lorlatinib is typically used as long as the patient is deriving clinical benefit from the therapy without experiencing unacceptable toxicity. The duration of use can vary based on individual response and tolerance.
How do I take Lorlatinib?
Lorlatinib should be taken orally once daily, with or without food, at the same time each day. Patients should avoid grapefruit and grapefruit juice, as they can interact with the medication. It is important to follow the healthcare provider's instructions and not to chew, crush, or split the tablets.
How should I store Lorlatinib?
Lorlatinib should be stored at room temperature, between 68°F to 77°F (20°C to 25°C). It should be kept in its original container, tightly closed, and out of reach of children. Avoid storing it in the bathroom to prevent exposure to moisture.
What is the usual dose of Lorlatinib?
The usual daily dose of Lorlatinib for adults is 100 mg taken orally once daily, with or without food. There is no established dose for children as the safety and effectiveness of Lorlatinib in pediatric patients have not been established.
Warnings and Precautions
Can I take Lorlatinib with other prescription drugs?
Lorlatinib interacts with strong CYP3A inducers, which can significantly reduce its effectiveness and increase the risk of liver damage. It is also affected by strong CYP3A inhibitors, which can increase the risk of side effects. Patients should inform their healthcare provider of all medications they are taking to avoid harmful interactions.
Can Lorlatinib be taken safely while breastfeeding?
Women are advised not to breastfeed during treatment with Lorlatinib and for 7 days after the final dose due to the potential for serious adverse reactions in breastfed infants. It is important to discuss alternative feeding options with a healthcare provider.
Can Lorlatinib be taken safely while pregnant?
Lorlatinib can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should use effective non-hormonal contraception during treatment and for at least 6 months after the final dose. Males with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the final dose.
Is Lorlatinib safe for the elderly?
There are no specific dosage adjustments recommended for elderly patients taking Lorlatinib. However, as with any medication, elderly patients should be monitored closely for side effects and interactions with other medications they may be taking. It is important to follow the healthcare provider's guidance and report any unusual symptoms.
Who should avoid taking Lorlatinib?
Important warnings for Lorlatinib include the risk of serious hepatotoxicity when used with strong CYP3A inducers, central nervous system effects, hyperlipidemia, atrioventricular block, interstitial lung disease, hypertension, and hyperglycemia. It is contraindicated in patients taking strong CYP3A inducers due to the risk of severe liver damage.
